1. Two formulations (BNO 3731, BNO 3732) were evaluated for AD treatment.
2. 100 participants enrolled; 94 completed the trial.
3. 53% reduction in peak itch intensity noted at 4 weeks.
4. 54% decrease in RECAP scores during first month.
5. 93% of participants satisfied with the treatments.
6. Minimal corticosteroid use during the trial.
7. Significant improvements in skin barrier markers and patient tolerability.
8. Study suggests herbal emollients as non-steroidal AD management options.

Source: Acta Dermato-Venereologica